The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...

In a study published in Cell Stem Cell, scientists tested retinal pigment epithelial stem cells in a phase 1/2a clinical trial. The cells were obtained from adult postmortem eye tissue. These ...

A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...

University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...

The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...

A wireless implant helped patients with severe macular degeneration regain usable vision. The results point toward a new ...

University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...

Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.

The clinical trial enrolled 38 adults aged 60 and older who had advanced geographic atrophy, the late stage of macular ...

Menlo Park resident Carmen Caricchio is on a quest to cure childhood inherited retinal diseases, a group of rare conditions that cause the degeneration of the retina and can lead to vision impairment ...